Aberrant apolipoprotein C-III glycosylation in glycogen storage disease type III and IX

Metabolism: Clinical and Experimental

Volumn 82, Issue , 2018, Pages 135-141

  Ondruskova, Nina ^a   Honzik, Tomas ^a   Kolarova, Hana ^a   Pakanova, Zuzana ^b   Mucha, Jan ^b   Zeman, Jiri ^a   Hansikova, Hana ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Apolipoprotein C III; Diagnostic marker; Glycogen storage disorders; Hypertriglyceridemia; O glycosylation

Indexed keywords

APOLIPOPROTEIN C3; TRANSFERRIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLYCOGEN STORAGE DISEASE; GLYCOGEN STORAGE DISEASE TYPE 0; GLYCOGEN STORAGE DISEASE TYPE 1A; GLYCOGEN STORAGE DISEASE TYPE 3; GLYCOGEN STORAGE DISEASE TYPE 9; GLYCOSYLATION; HUMAN; HYPERTRIGLYCERIDEMIA; INFANT; ISOELECTRIC FOCUSING; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIALYLATION; TRANSFERRIN BLOOD LEVEL; YOUNG ADULT; METABOLISM;

ADOLESCENT; ADULT; APOLIPOPROTEIN C-III; CHILD; CHILD, PRESCHOOL; FEMALE; GLYCOGEN STORAGE DISEASE; GLYCOGEN STORAGE DISEASE TYPE III; GLYCOSYLATION; HUMANS; INFANT; ISOELECTRIC FOCUSING; MALE; TRANSFERRIN; YOUNG ADULT;

EID: 85042766238     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2018.01.004     Document Type: Article

References (43)

1. Wopereis, S., Grünewald, S., Huijben, K.M., Morava, E., Mollicone, R., van Engelen, B.G., et al. Transferrin and apolipoprotein C-III isofocusing are complementary in the diagnosis of N- and O-glycan biosynthesis defects. Clin Chem 53 (2007), 180–187.
2. Péanne, R., de Lonlay, P., Foulquier, F., Kornak, U., Lefeber, D.J., Morava, E., et al. Congenital disorders of glycosylation (CDG): quo vadis?. Eur J Med Genet, 2017, 10.1016/j.ejmg.2017.10.012.
3. Kornak, U., Reynders, E., Dimopoulou, A., van Reeuwijk, J., Fischer, B., Rajab, A., et al. Group AD-tS: impaired glycosylation and cutis laxa caused by mutations in the vesicular H+-ATPase subunit ATP6V0A2. Nat Genet 40 (2008), 32–34.
4. Spaapen, L.J., Bakker, J.A., van der Meer, S.B., Sijstermans, H.J., Steet, R.A., Wevers, R.A., et al. Clinical and biochemical presentation of siblings with COG-7 deficiency, a lethal multiple O- and N-glycosylation disorder. J Inherit Metab Dis 28 (2005), 707–714.
5. Foulquier, F., Vasile, E., Schollen, E., Callewaert, N., Raemaekers, T., Quelhas, D., et al. Conserved oligomeric Golgi complex subunit 1 deficiency reveals a previously uncharacterized congenital disorder of glycosylation type II. Proc Natl Acad Sci U S A 103 (2006), 3764–3769.
6. Foulquier, F., Ungar, D., Reynders, E., Zeevaert, R., Mills, P., García-Silva, M.T., et al. A new inborn error of glycosylation due to a Cog8 deficiency reveals a critical role for the Cog1-Cog8 interaction in COG complex formation. Hum Mol Genet 16 (2007), 717–730.
7. Paesold-Burda, P., Maag, C., Troxler, H., Foulquier, F., Kleinert, P., Schnabel, S., et al. Deficiency in COG5 causes a moderate form of congenital disorders of glycosylation. Hum Mol Genet 18 (2009), 4350–4356.
8. Lübbehusen, J., Thiel, C., Rind, N., Ungar, D., Prinsen, B.H., de Koning, T.J., et al. Fatal outcome due to deficiency of subunit 6 of the conserved oligomeric Golgi complex leading to a new type of congenital disorders of glycosylation. Hum Mol Genet 19 (2010), 3623–3633.
9. Kodera, H., Ando, N., Yuasa, I., Wada, Y., Tsurusaki, Y., Nakashima, M., et al. Mutations in COG2 encoding a subunit of the conserved oligomeric golgi complex cause a congenital disorder of glycosylation. Clin Genet 87 (2015), 455–460.
10. Testa, R., Vanhooren, V., Bonfigli, A.R., Boemi, M., Olivieri, F., Ceriello, A., et al. N-glycomic changes in serum proteins in type 2 diabetes mellitus correlate with complications and with metabolic syndrome parameters. PLoS One, 10, 2015, e0119983.
11. Savinova, O.V., Fillaus, K., Jing, L., Harris, W.S., Shearer, G.C., Reduced apolipoprotein glycosylation in patients with the metabolic syndrome. PLoS One, 9, 2014, e104833.
12. Bilen, O., Altun, Z., Arslan, N., Onvural, B., Akan, P., Coker, C., The effect of malnutrition on protein glycosylation in children. Iran J Pediatr 24 (2014), 273–279.
13. Chrostek, L., Cylwik, B., Gindzienska-Sieskiewicz, E., Gruszewska, E., Szmitkowski, M., Sierakowski, S., Sialic acid level reflects the disturbances of glycosylation and acute-phase reaction in rheumatic diseases. Rheumatol Int 34 (2014), 393–399.
14. Allen, A.C., Abnormal glycosylation of IgA: is it related to the pathogenesis of IgA nephropathy?. Nephrol Dial Transplant 10 (1995), 1121–1124.
15. Munce, T., Heussler, H.S., Bowling, F.G., Analysis of N- and O-linked protein glycosylation in children with Prader-Willi syndrome. J Intellect Disabil Res 54 (2010), 929–937.
16. Harvey, S.B., Zhang, Y., Wilson-Grady, J., Monkkonen, T., Nelsestuen, G.L., Kasthuri, R.S., et al. O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease. J Proteome Res 8 (2009), 603–612.
17. Stojkovic, T., Vissing, J., Petit, F., Piraud, M., Orngreen, M.C., Andersen, G., et al. Muscle glycogenosis due to phosphoglucomutase 1 deficiency. N Engl J Med 361 (2009), 425–427.
18. Timal, S., Hoischen, A., Lehle, L., Adamowicz, M., Huijben, K., Sykut-Cegielska, J., et al. Gene identification in the congenital disorders of glycosylation type I by whole-exome sequencing. Hum Mol Genet 21 (2012), 4151–4161.
19. Kilimann, M.W., Oldfors, A., Glycogen pathways in disease: new developments in a classical field of medical genetics. J Inherit Metab Dis 38 (2015), 483–487.
20. Saudubray, J.-M., Baumgartner, M.R., Walter, J.H., Inborn metabolic diseases: diagnosis and treatment. 2016, Springer, 121–135.
21. Beauchamp, N.J., Dalton, A., Ramaswami, U., Niinikoski, H., Mention, K., Kenny, P., et al. Glycogen storage disease type IX: high variability in clinical phenotype. Mol Genet Metab 92 (2007), 88–99.
22. Roscher, A., Patel, J., Hewson, S., Nagy, L., Feigenbaum, A., Kronick, J., et al. The natural history of glycogen storage disease types VI and IX: long-term outcome from the largest metabolic center in Canada. Mol Genet Metab 113 (2014), 171–176.
23. Davit-Spraul, A., Piraud, M., Dobbelaere, D., Valayannopoulos, V., Labrune, P., Habes, D., et al. Liver glycogen storage diseases due to phosphorylase system deficiencies: diagnosis thanks to non invasive blood enzymatic and molecular studies. Mol Genet Metab 104 (2011), 137–143.
24. Tang, N.L., Hui, J., Young, E., Worthington, V., To, K.F., Cheung, K.L., et al. A novel mutation (G233D) in the glycogen phosphorylase gene in a patient with hepatic glycogen storage disease and residual enzyme activity. Mol Genet Metab 79 (2003), 142–145.
25. Burwinkel, B., Bakker, H.D., Herschkovitz, E., Moses, S.W., Shin, Y.S., Kilimann, M.W., Mutations in the liver glycogen phosphorylase gene (PYGL) underlying glycogenosis type VI. Am J Hum Genet 62 (1998), 785–791.
26. Morava, E., Galactose supplementation in phosphoglucomutase-1 deficiency; review and outlook for a novel treatable CDG. Mol Genet Metab 112 (2014), 275–279.
27. Gadomski, T., Wong, S., Honzik, T., Misfeld, A., Koch, D., Brocke, K., et al. Oral galactose supplementation in PGM1-CDG: as sweet as it sounds?. J Inherit Metab Dis 38 (2015), S38–S39.
28. Tegtmeyer, L.C., Rust, S., van Scherpenzeel, M., Ng, B.G., Losfeld, M.E., Timal, S., et al. Multiple phenotypes in phosphoglucomutase 1 deficiency. N Engl J Med 370 (2014), 533–542.
29. Ondrušková N., Honzík, T., Kytnarová J., Matoulek, M., Zeman, J., Hansíková H., Isoelectric focusing of serum apolipoprotein C-III as a sensitive screening method for the detection of O-glycosylation disturbances. Prague Med Rep 116 (2015), 73–86.
30. Wopereis, S., Morava, E., Grünewald, S., Adamowicz, M., Huijben, K.M., Lefeber, D.J., et al. Patients with unsolved congenital disorders of glycosylation type II can be subdivided in six distinct biochemical groups. Glycobiology 15 (2005), 1312–1319.
31. Wada, Y., Kadoya, M., Okamoto, N., Mass spectrometry of apolipoprotein C-III, a simple analytical method for mucin-type O-glycosylation and its application to an autosomal recessive cutis laxa type-2 (ARCL2) patient. Glycobiology 22 (2012), 1140–1144.
32. Yassine, H.N., Trenchevska, O., Ramrakhiani, A., Parekh, A., Koska, J., Walker, R.W., et al. The association of human apolipoprotein C-III sialylation proteoforms with plasma triglycerides. PLoS One, 10, 2015, e0144138.
33. Hayee, B., Antonopoulos, A., Murphy, E.J., Rahman, F.Z., Sewell, G., Smith, B.N., et al. G6PC3 mutations are associated with a major defect of glycosylation: a novel mechanism for neutrophil dysfunction. Glycobiology 21 (2011), 914–924.
34. Raval, K.K., Tao, R., White, B.E., De Lange, W.J., Koonce, C.H., Yu, J., et al. Pompe disease results in a Golgi-based glycosylation deficit in human induced pluripotent stem cell-derived cardiomyocytes. J Biol Chem 290 (2015), 3121–3136.
35. Schjoldager, K.T., Clausen, H., Site-specific protein O-glycosylation modulates proprotein processing - deciphering specific functions of the large polypeptide GalNAc-transferase gene family. Biochim Biophys Acta 2012 (1820), 2079–2094.
36. Marucci, A., di Mauro, L., Menzaghi, C., Prudente, S., Mangiacotti, D., Fini, G., et al. GALNT2 expression is reduced in patients with type 2 diabetes: possible role of hyperglycemia. PLoS One, 8, 2013, e70159.
37. Nomura, F., Ohnishi, K., Koen, H., Hiyama, Y., Nakayama, T., Itoh, Y., et al. Serum cholinesterase in patients with fatty liver. J Clin Gastroenterol 8 (1986), 599–602.
38. Sobenin, I.A., Salonen, J.T., Zhelankin, A.V., Melnichenko, A.A., Kaikkonen, J., Bobryshev, Y.V., et al. Low density lipoprotein-containing circulating immune complexes: role in atherosclerosis and diagnostic value. Biomed Res Int, 2014, 2014, 205697.
39. Sacks, F.M., Alaupovic, P., Moye, L.A., Cole, T.G., Sussex, B., Stampfer, M.J., et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial. Circulation 102 (2000), 1886–1892.
40. Pek, S.L.T., Sum, C.F., Yeoh, L.Y., Lee, S.B.M., Tang, W.E., Lim, S.C., et al. Association of apolipoprotein-CIII (apoC-III), endothelium-dependent vasodilation and peripheral neuropathy in a multi-ethnic population with type 2 diabetes. Metabolism 72 (2017), 75–82.
41. D'Avila, F., Tringali, C., Papini, N., Anastasia, L., Croci, G., Massaccesi, L., et al. Identification of lysosomal sialidase NEU1 and plasma membrane sialidase NEU3 in human erythrocytes. J Cell Biochem 114 (2013), 204–211.
42. Tertov, V.V., Kaplun, V.V., Sobenin, I.A., Boytsova, E.Y., Bovin, N.V., Orekhov, A.N., Human plasma trans-sialidase causes atherogenic modification of low density lipoprotein. Atherosclerosis 159 (2001), 103–115.
43. Rymen, D., Winter, J., Van Hasselt, P.M., Jaeken, J., Kasapkara, C., Gokçay, G., et al. Key features and clinical variability of COG6-CDG. Mol Genet Metab 116 (2015), 163–170.